Close Menu

NEW YORK – OncoCyte said after the close of the market on Friday that it has entered into an agreement to acquire all of the outstanding capital stock of privately held Insight Genetics, including a lung cancer immunotherapy test in development by the firm.

According to OncoCyte, the acquisition also gives it access to IG's existing pharma services infrastructure, which includes a CLIA-certified and CAP-accredited lab, and a menu of single-gene tests for various actionable biomarkers, including two emerging therapeutic targets, RET and NTRK.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.

The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.

In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.

According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.